The boss of Greggs has linked declining profits and customer demand for "smaller portions" to the rising popularity of appetite-suppressing drugs. This trend is pushing the bakery chain, alongside other retailers like Tesco, to adapt their product offerings to appeal to a more health-conscious market seeking protein and fiber-rich options.

• CEO Roisin Currie stated that the firm is introducing products like its egg-pot to cater to customers on GLP-1 drugs.
• Tesco Chief Executive Ken Murphy noted that a trend towards healthier eating contributed to growth in their fresh produce sales.
• Consumer analyst Clive Black from Shore Capital suggested that a slight dip in Christmas grocery volumes could indicate the impact of glucagon-peptide (GLP) drugs on eating habits.